Purpose: Finding the long-missed meaning
Cancer survivor Missy Pappion is happy at Boehringer Ingelheim after climbing the corporate ladder
Search
Ukraine Help: In a nine-seater to Poland
Boehringer Ingelheim employee Eugen Pushchyk rescues refugees from Ukraine
About Boehringer Ingelheim Partnering Days
Find out more about our partnering days and how we can work together to accelerate your science
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Boehringer Ingelheim Innovation Prize
Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
Welcome to Innovation at Boehringer Ingelheim
Watch our video and find out more about innovation at Boehringer Ingelheim.
One step further in fighting rabies in Vietnam
A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages.
Finding the right inhaler for you
Living with a chronic respiratory disease can make life complicated. This discussion guide can be used to help start a conversation with a healthcare professional about inhaler choice.
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
"To join Boehringer Ingelheim was the best ever decision"
Pharmacologist Michael Mark worked for us for 34 years. He played a key role in the research and development of several medications. Watch our video and discover our job opportunities.
Making sustainable medicines through eco-design
Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Closing healthcare gaps with continued vaccination campaigns
How we continue combating rabies through collaborative efforts and the use of drone delivery in rural Kenya.
Boehringer Ingelheim Social Engagements
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Research ruminant animal health well-being
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Advances in vectored vaccines for poultry
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.
LastMile initiative to address barriers in animal healthcare
The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African
European Metacam® indication expanded to guinea pigs
Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Partnership to further develop pet market in China
Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
STOP Rabies: moving towards elimination
Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
A career at the intersection of science and marketing
A member of the Animal Health digital marketing team, our colleague Missy talks about her purpose to bring transformative technologies to the vet community
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371